Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C

Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir. No prior reports exist of colitis secondary to either drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarkar, Souvik, Mitchell, Kisha A., Lim, Joseph K., Oikonomou, Ioannis, Jakab, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612757/
https://www.ncbi.nlm.nih.gov/pubmed/26504877
http://dx.doi.org/10.14309/crj.2015.96
Descripción
Sumario:Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir. No prior reports exist of colitis secondary to either drug or their combination. We report a patient with no prior history of inflammatory bowel disease who developed significant bloody diarrhea within 2 weeks of sofosbuvir/simeprevir initiation. Colonoscopy and biopsy confirmed pancolitis, which responded to mesalamine and completion of sofosbuvir/simeprevir.

Ejemplares similares